Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513

Watchlist Manager
Chengdu Easton Biopharmaceuticals Co Ltd Logo
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Watchlist
Price: 35.07 CNY -3.55% Market Closed
Market Cap: 6.2B CNY
Have any thoughts about
Chengdu Easton Biopharmaceuticals Co Ltd?
Write Note

Chengdu Easton Biopharmaceuticals Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Chengdu Easton Biopharmaceuticals Co Ltd
Cost of Revenue Peer Comparison

Comparables:
H
3692
600436
600276
000538
S
688506

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Cost of Revenue
-ÂĄ225.9m
CAGR 3-Years
-28%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cost of Revenue
-ÂĄ1B
CAGR 3-Years
-9%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cost of Revenue
-ÂĄ5.9B
CAGR 3-Years
-15%
CAGR 5-Years
-14%
CAGR 10-Years
-24%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cost of Revenue
-ÂĄ3.9B
CAGR 3-Years
1%
CAGR 5-Years
-6%
CAGR 10-Years
-11%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cost of Revenue
-ÂĄ28.7B
CAGR 3-Years
-3%
CAGR 5-Years
-8%
CAGR 10-Years
-9%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cost of Revenue
-ÂĄ242.3m
CAGR 3-Years
-6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Chengdu Easton Biopharmaceuticals Co Ltd's Cost of Revenue?
Cost of Revenue
-225.9m CNY

Based on the financial report for Dec 31, 2023, Chengdu Easton Biopharmaceuticals Co Ltd's Cost of Revenue amounts to -225.9m CNY.

What is Chengdu Easton Biopharmaceuticals Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-21%

Over the last year, the Cost of Revenue growth was -14%. The average annual Cost of Revenue growth rates for Chengdu Easton Biopharmaceuticals Co Ltd have been -28% over the past three years , -21% over the past five years .

Back to Top